|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Merika E, Saif MW, Katz A, Syrigos K and
Morse M: Review. Colon cancer vaccines: an update. In Vivo.
24:607–628. 2010.PubMed/NCBI
|
|
4
|
Chung MY, Lim TG and Lee KW: Molecular
mechanisms of chemopreventive phytochemicals against
gastroenterological cancer development. World J Gastroenterol.
19:984–993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Banerjee S, Padhye S, Azmi A, et al:
Review on molecular and therapeutic potential of thymoquinone in
cancer. Nutr Cancer. 62:938–946. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kundu J, Kim DH, Kundu JK and Chun KS:
Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via
Nrf2/ARE activation: Akt and AMPKα as upstream targets. Food Chem
Toxicol. 65:18–26. 2014.PubMed/NCBI
|
|
7
|
Kundu JK, Liu L, Shin JW and Surh YJ:
Thymoquinone inhibits phorbol ester-induced activation of NF-κB and
expression of COX-2, and induces expression of cytoprotective
enzymes in mouse skin in vivo. Biochem Biophys Res Commun.
438:721–727. 2013.PubMed/NCBI
|
|
8
|
Lei X, Lv X, Liu M, et al: Thymoquinone
inhibits growth and augments 5-fluorouracil-induced apoptosis in
gastric cancer cells both in vitro and in vivo. Biochem Biophys Res
Commun. 417:864–868. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yi T, Cho SG, Yi Z, et al: Thymoquinone
inhibits tumor angiogenesis and tumor growth through suppressing
AKT and extracellular signal-regulated kinase signaling pathways.
Mol Cancer Ther. 7:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gali-Muhtasib H, Diab-Assaf M, Boltze C,
et al: Thymoquinone extracted from black seed triggers apoptotic
cell death in human colorectal cancer cells via a p53-dependent
mechanism. Int J Oncol. 25:857–866. 2004.PubMed/NCBI
|
|
11
|
Gali-Muhtasib H, Ocker M, Kuester D, et
al: Thymoquinone reduces mouse colon tumor cell invasion and
inhibits tumor growth in murine colon cancer models. J Cell Mol
Med. 12:330–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jafri SH, Glass J, Shi R, Zhang S, Prince
M and Kleiner-Hancock H: Thymoquinone and cisplatin as a
therapeutic combination in lung cancer: In vitro and in vivo. J Exp
Clin Cancer Res. 29:872010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaseb AO, Chinnakannu K, Chen D, et al:
Androgen receptor and E2F-1 targeted thymoquinone therapy for
hormone-refractory prostate cancer. Cancer Res. 67:7782–7788. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jrah-Harzallah H, Ben-Hadj-Khalifa S,
Almawi WY, Maaloul A, Houas Z and Mahjoub T: Effect of thymoquinone
on 1,2-dimethyl-hydrazine-induced oxidative stress during
initiation and promotion of colon carcinogenesis. Eur J Cancer.
49:1127–1135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Burz C, Berindan-Neagoe I, Balacescu O and
Irimie A: Apoptosis in cancer: key molecular signaling pathways and
therapy targets. Acta Oncol. 48:811–821. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin SJ and Green DR: Protease
activation during apoptosis: death by a thousand cuts? Cell.
82:349–352. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ihle JN: The Stat family in cytokine
signaling. Curr Opin Cell Biol. 13:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Slattery ML, Lundgreen A, Kadlubar SA,
Bondurant KL and Wolff RK: JAK/STAT/SOCS-signaling pathway and
colon and rectal cancer. Mol Carcinog. 52:155–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laird AD, Li G, Moss KG, et al: Src family
kinase activity is required for signal tranducer and activator of
transcription 3 and focal adhesion kinase phosphorylation and
vascular endothelial growth factor signaling in vivo and for
anchorage-dependent and -independent growth of human tumor cells.
Mol Cancer Ther. 2:461–469. 2003.
|
|
21
|
Berclaz G, Altermatt HJ, Rohrbach V,
Siragusa A, Dreher E and Smith PD: EGFR dependent expression of
STAT3 (but not STAT1) in breast cancer. Int J Oncol. 19:1155–1160.
2001.PubMed/NCBI
|
|
22
|
Chan KS, Carbajal S, Kiguchi K, Clifford
J, Sano S and DiGiovanni J: Epidermal growth factor
receptor-mediated activation of Stat3 during multistage skin
carcinogenesis. Cancer Res. 64:2382–2389. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, et al: Signal transducer and activator of transcription-3,
inflammation, and cancer: how intimate is the relationship? Ann NY
Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnston PA and Grandis JR: STAT3
signaling: anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Masuda M, Suzui M, Yasumatu R, et al:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
26
|
Dowlati A, Nethery D and Kern JA: Combined
inhibition of epidermal growth factor receptor and JAK/STAT
pathways results in greater growth inhibition in vitro than single
agent therapy. Mol Cancer Ther. 3:459–463. 2004.PubMed/NCBI
|
|
27
|
Kong L, Deng Z, Shen H and Zhang Y: Src
family kinase inhibitor PP2 efficiently inhibits cervical cancer
cell proliferation through down-regulating phospho-Src-Y416 and
phospho-EGFR-Y1173. Mol Cell Biochem. 348:11–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kopetz S: Targeting SRC and epidermal
growth factor receptor in colorectal cancer: rationale and progress
into the clinic. Gastrointest Cancer Res. 1:S37–S41.
2007.PubMed/NCBI
|
|
29
|
Mann JR, Backlund MG and DuBois RN:
Mechanisms of disease: Inflammatory mediators and cancer
prevention. Nat Clin Pract Oncol. 2:202–210. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Woo CC, Kumar AP, Sethi G and Tan KH:
Thymoquinone: potential cure for inflammatory disorders and cancer.
Biochem Pharmacol. 83:443–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
El-Najjar N, Chatila M, Moukadem H, et al:
Reactive oxygen species mediate thymoquinone-induced apoptosis and
activate ERK and JNK signaling. Apoptosis. 15:183–195. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gali-Muhtasib H, Kuester D, Mawrin C, et
al: Thymoquinone triggers inactivation of the stress response
pathway sensor CHEK1 and contributes to apoptosis in colorectal
cancer cells. Cancer Res. 68:5609–5618. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koka PS, Mondal D, Schultz M, Abdel-Mageed
AB and Agrawal KC: Studies on molecular mechanisms of growth
inhibitory effects of thymoquinone against prostate cancer cells:
role of reactive oxygen species. Exp Biol Med. 235:751–760. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hussain AR, Uddin S, Ahmed M, Al-Dayel F,
Bavi PP and Al-Kuraya KS: Phosphorylated IκBα predicts poor
prognosis in activated B-cell lymphoma and its inhibition with
thymoquinone induces apoptosis via ROS release. PLoS One.
8:e605402013.
|
|
35
|
Valassiadou KE, Stefanaki K, Tzardi M, et
al: Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21
proteins in colorectal adenocarcinomas. Anticancer Res.
17:2571–2576. 1997.PubMed/NCBI
|
|
36
|
Bonnotte B, Favre N, Moutet M, et al:
Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and
restores tumorigenicity of spontaneously regressive tumors. J
Immunol. 161:1433–1438. 1998.PubMed/NCBI
|
|
37
|
Dobi E, Monnien F, Kim S, et al: Impact of
STAT3 phosphorylation on the clinical effectiveness of
anti-EGFR-based therapy in patients with metastatic colorectal
cancer. Clin Colorectal Cancer. 12:28–36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corvinus FM, Orth C, Moriggl R, et al:
Persistent STAT3 activation in colon cancer is associated with
enhanced cell proliferation and tumor growth. Neoplasia. 7:545–555.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin Q, Lai R, Chirieac LR, et al:
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and
cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis
and cell cycle arrest of colon carcinoma cells. Am J Pathol.
167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Badr G, Mohany M and Abu-Tarboush F:
Thymoquinone decreases F-actin polymerization and the proliferation
of human multiple myeloma cells by suppressing STAT3
phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis.
10:236–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li F, Rajendran P and Sethi G:
Thymoquinone inhibits proliferation, induces apoptosis and
chemosensitizes human multiple myeloma cells through suppression of
signal transducer and activator of transcription 3 activation
pathway. Br J Pharmacol. 161:541–554. 2010. View Article : Google Scholar
|
|
42
|
Zhang X, Liu P, Zhang B, Mao H, Shen L and
Ma Y: Inhibitory effects of STAT3 decoy oligodeoxynucleotides on
human epithelial ovarian cancer cell growth in vivo. Int J
Mol Med. 32:623–628. 2013.PubMed/NCBI
|
|
43
|
Kanda N, Seno H, Konda Y, et al: STAT3 is
constitutively activated and supports cell survival in association
with survivin expression in gastric cancer cells. Oncogene.
23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Asanuma K, Tsuji N, Endoh T, Yagihashi A
and Watanabe N: Survivin enhances Fas ligand expression via
up-regulation of specificity protein 1-mediated gene transcription
in colon cancer cells. J Immunol. 172:3922–3929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin L, Liu A, Peng Z, et al: STAT3 is
necessary for proliferation and survival in colon cancer-initiating
cells. Cancer Res. 71:7226–7237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Forgue-Lafitte ME, Coudray AM, Breant B
and Mester J: Proliferation of the human colon carcinoma cell line
HT29: autocrine growth and deregulated expression of the c-myc
oncogene. Cancer Res. 49:6566–6571. 1989.PubMed/NCBI
|
|
47
|
Abukhdeir AM and Park BH: P21 and p27:
roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10:e192008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nourazarian AR, Najar AG, Farajnia S,
Khosroushahi AY, Pashaei-Asl R and Omidi Y: Combined EGFR and c-Src
antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers
inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer
Prev. 13:4751–4756. 2012. View Article : Google Scholar
|
|
49
|
Boehm AL, Sen M, Seethala R, et al:
Combined targeting of epidermal growth factor receptor, signal
transducer and activator of transcription-3, and Bcl-X(L) enhances
antitumor effects in squamous cell carcinoma of the head and neck.
Mol Pharmacol. 73:1632–1642. 2008. View Article : Google Scholar : PubMed/NCBI
|
